Updates are available Correction dated 2025-02-13
Click to view Correction: https://doi.org/10.1038/s41586-025-08764-y
-
Authors
Ikeda, Hideki https://orcid.org/0009-0000-1334-7597
Kawase, Katsushige https://orcid.org/0000-0001-6998-8481
Nishi, Tatsuya
Watanabe, Tomofumi https://orcid.org/0000-0003-4759-7871
Takenaga, Keizo https://orcid.org/0000-0002-5341-6742
Inozume, Takashi
Ishino, Takamasa
Aki, Sho https://orcid.org/0000-0002-5787-2075
Lin, Jason
Kawashima, Shusuke
Nagasaki, Joji
Ueda, Youki https://orcid.org/0000-0002-2627-8524
Suzuki, Shinichiro https://orcid.org/0000-0002-3870-2214
Makinoshima, Hideki https://orcid.org/0009-0001-8181-6241
Itami, Makiko
Nakamura, Yuki
Tatsumi, Yasutoshi https://orcid.org/0000-0003-2646-7410
Suenaga, Yusuke https://orcid.org/0000-0001-6902-5386
Morinaga, Takao
Honobe-Tabuchi, Akiko
Ohnuma, Takehiro
Kawamura, Tatsuyoshi
Umeda, Yoshiyasu
Nakamura, Yasuhiro
Kiniwa, Yukiko
Ichihara, Eiki
Hayashi, Hidetoshi https://orcid.org/0000-0001-8787-5587
Ikeda, Jun-ichiro
Hanazawa, Toyoyuki
Toyooka, Shinichi
Mano, Hiroyuki https://orcid.org/0000-0003-4645-0181
Suzuki, Takuji
Osawa, Tsuyoshi https://orcid.org/0000-0002-9479-6665
Kawazu, Masahito https://orcid.org/0000-0003-4146-3629
Togashi, Yosuke https://orcid.org/0000-0001-9910-0164
- License Information
-
More Information
Article History
Received: 5 January 2023
Accepted: 21 November 2024
First Online: 22 January 2025
Change Date: 13 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-025-08764-y
Competing interests
: T. Inozume. received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb and MSD outside this study. S.S. received honoraria from AstraZeneca outside this study. Yasuhiro Nakamura. received honoraria from Ono Pharmaceutical and Novartis Pharma outside this study. E.I. received grants from Janssen Pharmaceutical, Bristol-Myers Squibb, Takeda Pharmaceutical, Pfizer Japan and Ono Pharmaceutical; honoraria from AstraZeneca, Novartis Pharma, Janssen Pharmaceutical, Boehringer Ingelheim, Chugai Pharmaceutical, Eli Lilly Japan and Pfizer Japan outside this study. H.H. received research grants from AstraZeneca, Astellas Pharma, MSD, Ono Pharmaceutical, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Bristol-Myers Squibb, Eli Lilly Japan, Chugai Pharmaceutical, Daiichi Sankyo, Merck Serono, Merck Biopharma, Takeda Pharmaceutical, Taiho Pharmaceutical, SymBio Pharmaceuticals, AbbVie, inVentiv Health Japan, ICON Japan, Gritstone Oncology, Parexel International, Kissei Pharmaceutical, EPS, Syneos Health, Pfizer R&D Japan, A2 Healthcare, Quintiles/IQVIA Services Japan, EP-CRSU, Linical, Eisai, CMIC Shift Zero, Kyowa Hakko Kirin, Bayer Yakuhin, EPS International and Otsuka Pharmaceutical; honoraria from Amgen, AstraZeneca, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Janssen Pharmaceutical, Kyorin Pharmaceutical, Merck Biopharma, MSD, Novartis Pharmaceuticals, Ono Pharmaceutical, Taiho Pharmaceutical and Takeda Pharmaceutical; consulting fees from AstraZeneca, Boehringer Ingelheim Japan, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Guardant Health, Pfizer Japan, Shanghai Haihe Biopharma, Takeda Pharmaceutical and Merck Biopharma outside this study. Y. Togashi received research grants from KOTAI Biotechnologies, Daiichi-Sankyo, Ono Pharmaceutical, Bristol-Myers Squibb and KORTUC, and honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, AstraZeneca, Chugai Pharmaceutical and MSD outside this study. All other authors declare that they have no competing financial interests.
